1. Home
  2. MD vs APLS Comparison

MD vs APLS Comparison

Compare MD & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pediatrix Medical Group Inc.

MD

Pediatrix Medical Group Inc.

HOLD

Current Price

$20.80

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Logo Apellis Pharmaceuticals Inc.

APLS

Apellis Pharmaceuticals Inc.

HOLD

Current Price

$17.07

Market Cap

2.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MD
APLS
Founded
1979
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Hospital/Nursing Management
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
2.2B
IPO Year
1996
2015

Fundamental Metrics

Financial Performance
Metric
MD
APLS
Price
$20.80
$17.07
Analyst Decision
Hold
Buy
Analyst Count
4
21
Target Price
$20.00
$31.65
AVG Volume (30 Days)
728.5K
1.9M
Earning Date
05-05-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
263.03
112.50
EPS
1.94
0.20
Revenue
$1,913,849,000.00
$1,003,782,000.00
Revenue This Year
$3.72
N/A
Revenue Next Year
$2.62
$18.21
P/E Ratio
$10.56
$84.90
Revenue Growth
N/A
28.46
52 Week Low
$11.84
$16.10
52 Week High
$24.99
$30.48

Technical Indicators

Market Signals
Indicator
MD
APLS
Relative Strength Index (RSI) 57.19 29.92
Support Level $20.72 N/A
Resistance Level $21.98 $20.65
Average True Range (ATR) 0.61 0.65
MACD 0.18 -0.04
Stochastic Oscillator 76.58 8.08

Price Performance

Historical Comparison
MD
APLS

About MD Pediatrix Medical Group Inc.

Pediatrix Medical Group Inc provides physician services to hospitals, intensive care units, and other medical units. The services provided by the company include maternal care for expectant mothers, intensive care for premature babies, cardiology care for infants suffering from heart defects, and anesthesia care during surgeries, among others. The company operates only under one segment which provides physician services including newborn, maternal-fetal, and other pediatric subspecialty care. It generates majority of the revenue through neonatology and other pediatric subspecialties.

About APLS Apellis Pharmaceuticals Inc.

Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. Currently it has two marketed drugs that target C3, the central protein in the complement cascade: SYFOVRE (pegcetacoplan injection) and EMPAVELI (pegcetacoplan).

Share on Social Networks: